Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Cancer Tracker

Implantable device monitors tumors

Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but offer only a snapshot of the tumor at a single moment in time. Monitoring a tumor for weeks or months after the biopsy would be much more valuable, says Michael Cima, an MIT professor of materials science and engineering. He has developed the first implantable device that can do just that.

Mini monitor Grad student Christophoros Vassiliou ‘04, MEng ‘06 (right), holds the cancer monitoring device that Professor Michael Cima (left) developed with him and Grace Kim, PhD ‘08.

“What this does is basically take the lab and put it in the patient,” says Cima, who is also an investigator at the David H. Koch Institute for Integrative Cancer Research at MIT.

This story is part of the September/October 2009 Issue of the MIT News Magazine
See the rest of the issue
Subscribe

The device, which could be implanted at the time of a biopsy, would provide up-to-the-minute information about a tumor–whether it’s growing or shrinking, whether chemotherapy drugs have reached it, and whether it has metastasized or is about to do so. In a paper published in the journal Biosensors & Bioelectronics, Cima and his colleagues recently reported that their device successfully tracked for one month a chemical produced by human tumors growing in mice.

The cylindrical, five-­millimeter implant contains magnetic nanoparticles coated with antibodies specific to target molecules such as hormones produced by tumor cells. When target molecules enter the implant through a semipermeable membrane, they bind to the particles and cause them to clump together. Magnetic resonance imaging can detect the clumps–and track whether they’re getting bigger or smaller.

Implants that can test for pH levels, which reveal a tumor’s metabolism and its response to chemotherapy, could be commercially available in a few years, Cima says. These would be followed by devices that test for complex chemicals such as hormones and drugs.

Unlike biopsies, such technologies could alert doctors that the original tumor has started shedding cancer cells before those cells can form new tumors. “This is one of the tools we’re going to need if we’re going to turn cancer from a death sentence to a manageable disease,” Cima says.

The latest Insider Conversation is live! Listen to the story behind the story.

Subscribe today
Already a Premium subscriber? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.